Accelr8 Shares up 60 Percent on MRSA Dx Patent Allowance

Oct 18, 2007

NEW YORK (GenomeWeb News) — Shares in Accelr8 were up more than 60 percent this afternoon after the company said the US Patent and Trademark Office gave it a notice of allowance on the first patent related to its diagnostic platform.

Shares in the company were up 1.36 at $3.82 in late-afternoon trading today.

The company said the methods covered by the patent will enable its BACcel system to "quickly identify major multiple-drug-resistant bacteria and their resistance mechanisms."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Breaking News

The Scan

Bit of Uncertainty

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Effect of Sex

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Better Microbes

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

This Week in PNAS

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.

Main menu